journal
https://read.qxmd.com/read/38537395/efficacy-and-safety-of-selinexor-for-patients-with-relapsed-and-refractory-multiple-myeloma-a-meta-analysis
#1
REVIEW
Laila Shafei, Shaima Bashir, Esther W Chan, Dina Abushanab, Anas Hamad, Daoud Al-Badriyeh
PURPOSE: Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM. METHODS: We searched PubMed, EMBASE, CENTRAL, clinicaltrial.gov, and google scholar, until May 2023, studies about selinexor use in RRMM. The outcome measures of interest were primarily efficacy outcomes, in addition to safety outcomes...
March 26, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38494387/targeting-ret-alterations-in-non-small-cell-lung-cancer
#2
JOURNAL ARTICLE
Go Nishikawa, Mark A Klein
Rearranged during transfection (RET) alterations, which lead to aberrant activation of the RET proto-oncogene, have been identified in various cancers. In non-small cell lung cancer (NSCLC), RET mutations often manifest as RET fusion genes and are observed in 1-2 % of patients with NSCLC. In recent years, selective RET inhibitors such as selpercatinib and pralsetinib, approved by the Food and Drug Administration (FDA) in 2020, have been part of the revolutionary changes in the treatment landscape for non-small cell lung cancer...
March 16, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38492281/development-and-validation-of-nomogram-models-for-predicting-postoperative-prognosis-of-early-stage-laryngeal-squamous-cell-carcinoma
#3
JOURNAL ARTICLE
Xu Juan, Huang Jiali, Liu Ziqi, Zhang Liqing, Zhou Han
BACKGROUND: We aimed to investigate the postoperative prognosis in patients with early-stage laryngeal squamous cell carcinoma (LSCC) in association with the preoperative blood markers and clinicopathological characteristics and to develop nomograms for individual risk prediction. METHODS: The clinical data of 353 patients with confirmed early-stage LSCC between 2009 and 2018 were retrospectively retrieved from the First Affiliated Hospital with Nanjing Medical University...
March 15, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38490881/familial-and-social-implications-of-breast-and-gynaecological-cancer-in-kerala-india
#4
JOURNAL ARTICLE
Lorane Scaria, Saju Madavanakadu Devassy, Lynette Joubert
BACKGROUND: Due to the paucity of reliable data to determine the components of family-based comprehensive care for cancer in India, we explored the familial implications of gynaecological and breast cancer diagnosis and treatment through a mixed-method study. METHODS: The mixed method study included 130 women aged above 18 with a confirmed diagnosis of gynaecological or breast cancer recruited from three selected tertiary hospitals in Kerala, India. Information on quality of life (36-Item Short Form Survey (SF-36)), psychological distress (distress thermometer), and the familial, interpersonal, social, and community impacts of cancer (semi-structured interview guide) were elicited...
March 14, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38480028/enhancing-skin-lesion-classification-with-advanced-deep-learning-ensemble-models-a-path-towards-accurate-medical-diagnostics
#5
JOURNAL ARTICLE
Kavitha Munuswamy Selvaraj, Sumathy Gnanagurusubbiah, Reena Roy Roby Roy, Jasmine Hephzipah John Peter, Sarala Balu
Skin cancer, including the highly lethal malignant melanoma, poses a significant global health challenge with a rising incidence rate. Early detection plays a pivotal role in improving survival rates. This study aims to develop an advanced deep learning-based approach for accurate skin lesion classification, addressing challenges such as limited data availability, class imbalance, and noise. Modern deep neural network designs, such as ResNeXt101, SeResNeXt101, ResNet152V2, DenseNet201, GoogLeNet, and Xception, which are used in the study and ze optimised using the SGD technique...
March 13, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38480027/met-alterations-in-advanced-non-small-cell-lung-cancer
#6
JOURNAL ARTICLE
Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Badi El Osta
Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify oncogenic drivers linked with better outcomes when treated upfront with targeted therapies. Mesenchymal-epithelial transition factor (MET) alterations are present in up to 60% of non-small cell lung cancer and are associated with a poor prognosis...
March 12, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38341356/targeting-mek-in-non-small-cell-lung-cancer
#7
JOURNAL ARTICLE
Matthew S Lara, Collin M Blakely, Jonathan W Riess
The mitogen-activated protein kinase (MAPK or MEK) pathway modulates tumor cell survival and proliferation in non-small cell lung cancer (NSCLC). Unlike RAS or EGFR, activating mutations in MEK are exceedingly rare in NSCLC. Instead, enhanced activation of the MEK pathway is often linked to increased signaling by upstream oncogenic driver mutations. Thus far, MEK inhibitor monotherapy has shown little promise. However, treatment strategies involving MEK inhibition in combination with other targeted therapies in other oncogene-driven NSCLC has proven to be encouraging...
February 9, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38330781/the-role-of-coenzyme-q10-as-a-preventive-and-therapeutic-agent-for-the-treatment-of-cancers
#8
REVIEW
Ghazal Ghasempour Dabaghi, Mehrdad Rabiee Rad, Mahtab Mohammad-Zamani, Atieh Karimi Shervedani, Farnaz Bahrami-Samani, Kiyan Heshmat-Ghahdarijani
Currently, several options are available for the prevention and treatment of cancers; however, many limitations remain with these approaches. Recently, antioxidants have become important preventive and therapeutic alternatives with few adverse events and minimum cost. Coenzyme Q10 (CoQ10) is a naturally occurring component that performs an anticancer function by reducing oxidative stress. CoQ10 supplementation as an adjuvant therapy offers more progress in the elimination and development of cancers. This review aimed to critically assess and summarize the implication of CoQ10 in cancers, highlighting possible mechanisms, and future directions of research for the standardization of the current regimen for cancer prevention and treatment...
February 7, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38311523/current-management-of-uncommon-egfr-mutations-in-non-small-cell-lung-cancer
#9
JOURNAL ARTICLE
Jonathan Q Trinh, Omar Abughanimeh
Epidermal growth factor receptor (EGFR) mutations are frequently implicated in non-small cell lung cancer (NSCLC). Though these typically involve exon 19 in-frame deletions or L858R mutations in exon 21, uncommon EGFR mutations comprise 10-15 % of all EGFR mutations. These most frequently include G719X mutations in exon 18, L861Q mutations in exon 21, S768I mutations in exon 20, and in-frame insertions and/or duplications in exon 20. It is crucial to understand these distinct variants and their specific responses to active treatment options to optimize care...
February 3, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38309146/illuminating-the-breast-cancer-survival-rates-among-southeast-asian-women-a-systematic-review-and-meta-analysis-spanning-four-decades
#10
REVIEW
Duc Tran Quang, Thanh Luong Thi, Khanh Nguyen Di, Chi Vu Thi Quynh, Huyen Nguyen Thi Hoa, Quang Phan Ngoc
In Southeast Asia, breast cancer is the most prevalent cancer among women and ranks as the second leading cause of cancer-related deaths. This systematic review and meta-analysis, encompassing 27 observational cohort studies with a minimum one-year follow-up period, aimed to examine temporal trends in breast cancer survival rates. Among the subset of five out of eleven Southeast Asian nations with available data, our analysis revealed pooled survival rates of 88.8 % at 1 year, 73.8 % at 3 years, 70.8 % at 5 years, and 49...
February 2, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38281845/current-and-emerging-strategies-for-the-management-of-advanced-metastatic-lung-neuroendocrine-tumors
#11
JOURNAL ARTICLE
Megan Rutherford, Margaret Wheless, Katharine Thomas, Robert A Ramirez
Pulmonary neuroendocrine tumors represent a spectrum of disease ranging from typical carcinoid tumors to small cell lung cancers. The incidence of low-grade pulmonary NETs has been increasing, leading to improved awareness and the need for more treatment options for this rare cancer. Somatostatin analogs continue to be the backbone of therapy and may be followed or accompanied by targeted therapy, chemotherapy, and immune therapy. The recent addition of peptide receptor radionuclide therapy (PRRT) to the treatment armamentarium of NETs has led to the development of targeted alpha therapy to overcome PRRT resistance and minimize off-target adverse effects...
January 27, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38211418/association-between-time-from-diagnosis-to-treatment-and-survival-of-patients-with-nasopharyngeal-carcinoma-a-population-based-cohort-study
#12
JOURNAL ARTICLE
Xiaoyuan Wei, Siting Yu, Jun Wang, Zhongzheng Xiang, Lei Liu, Yu Min
BACKGROUND: Treatment delays have frequently been observed in cancer patients. Whether the treatment delays would impair the survival of patients with nasopharyngeal carcinoma (NPC) is still unclear. METHODS: The data were derived from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. Patients were divided into groups of timely treatment (<1 month), intermediate delay (1 and 2 months), and long delay (3-6 months). The influence of different treatment delay intervals on long-term survival was evaluated by multivariate Cox regression analysis...
January 10, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38181630/blood-based-multi-cancer-detection-a-state-of-the-art-update
#13
REVIEW
Maria Farooq, Elyse Leevan, Jibran Ahmed, Brian Ko, Sarah Shin, Andre De Souza, Naoko Takebe
The early detection of cancer is a key goal of the National Cancer Plan formally released by the National Institutes of Health's (NIH) National Cancer Institute (NCI) in April 2023. To support this effort, many laboratories and vendors are developing multi-cancer detection (MCD) assays that interrogate blood and other bodily fluids for cancer-related biomarkers, most commonly circulating tumor DNA (ctDNA). While this approach holds promise for non-invasively detecting early signals of multiple different cancers and potentially reducing cancer-related mortality, there is a dearth of prospective clinical data to inform the deployment of MCD assays for cancer screening in the general adult population...
January 4, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38364336/prognostic-value-of-the-peripheral-blood-lymphocyte-monocyte-ratio-combined-with-18-f-fdg-pet-ct-in-patients-with-diffuse-large-b-cell-lymphoma
#14
JOURNAL ARTICLE
Wenke Wu, Lidong Zhao, Ying Wang, Peng Chen, Xiaoshuai Yuan, Lei Miao, Yuanxin Zhu, Jianping Mao, Zhimei Cai, Yajun Ji, Lei Wang, Tao Jia
OBJECTIVE: To explore the prognostic value of the peripheral blood lymphocyte/monocyte ratio (LMR) combined with 18 F-FDG PET/CT for diffuse large B-cell lymphoma (DLBCL). METHODS: The clinical data of 203 patients with primary DLBCL who were hospitalized to the First People's Hospital of Lianyungang between January 2017 and December 2022 were retrospectively analyzed. Before and after three courses of treatment, PET/CT was performed on forty DLBCL patients. The subject operating characteristic (ROC) curve has been employed to determine the most effective LMR cutoff points...
February 2024: Current Problems in Cancer
https://read.qxmd.com/read/38101085/a-novel-model-to-predict-the-risk-of-hematological-toxicity-in-lung-adenocarcinoma-patients-with-pemetrexed-plus-platinum-chemotherapy-based-on-real-world-data
#15
JOURNAL ARTICLE
Wei-Jing Gong, Peng Cao, Yi-Fei Huang, Ya-Ni Liu, Yu Yang, Rui Zhang, Qiang Li, San-Lan Wu, Yu Zhang
BACKGROUND: Pemetrexed plus platinum chemotherapy is the first-line treatment option for lung adenocarcinoma. However, hematological toxicity is major dose-limiting and even life-threatening. The ability to anticipate hematological toxicity is of great value for identifying potential chemotherapy beneficiaries with minimal toxicity and optimizing treatment. The study aimed to develop and validate a prediction model for hematologic toxicity based on real-world data. METHODS: Data from 1754 lung adenocarcinoma patients with pemetrexed plus platinum chemotherapy regimen as first-line therapy were used to establish and calibrate a risk model for hematological toxicity using multivariate and stepwise logistic regression analysis based on real-world data...
December 14, 2023: Current Problems in Cancer
https://read.qxmd.com/read/38096653/controversies-in-the-treatment-of-early-stage-oral-squamous-cell-carcinoma
#16
JOURNAL ARTICLE
Leonardo Ferrari, Paolo Cariati, Imanol Zubiate, Ángel Martínez-Sahuquillo Rico, Susana Arroyo Rodriguez, Rosa Maria Pulgar Encinas, Silvano Ferrari, Ildefonso Martínez Lara
The treatment of early-stage oral squamous cell carcinoma (OSCC) is still a controversial issue. Thanks to the 8th edition of TNM by AJCC there is a better distinction between the stages of OSCC. However, Stages I and II still share the same treatment protocol, even if the prognosis is radically different. A retrospective study has been conducted including 70 previously untreated patients with Stage I or II OSCC, treated with tumorectomy and selective neck dissection. The study focuses on the link between pT1/2 and various other factors, particularly histological grading, vascular and perineural invasion, local and cervical recurrence, surgical margins and overall survival...
December 13, 2023: Current Problems in Cancer
https://read.qxmd.com/read/38070464/the-diagnostic-value-of-serum-lncrna-catg00000112921-1-as-a-marker-of-multiple-myeloma
#17
JOURNAL ARTICLE
Jing Gao, Jing Qu, Bin Xiao, Qiyuan Huang, Chuiyu Zhu, Zichang Dai, Kunhe Wu, Linhai Li, Tao Zeng
BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disease. At present, numerous studies have shown that lncRNA plays a very important role in the occurrence, development and even drug resistance of multiple myeloma. It may become a potential diagnostic and prognostic marker of multiple myeloma and provide new ideas for targeted therapy. Based on the above research background, this study used gene chip technology to screen out the differentially expressed lncRNA in the serum of MM patients and healthy people, and verified more clinical serum samples to screen out the lncRNA with the largest difference as a biomarker for further research...
December 8, 2023: Current Problems in Cancer
https://read.qxmd.com/read/37845104/established-and-new-treatment-roadmaps-for-pleural-mesothelioma-opinions-of-the-turkish-collaborative-group
#18
REVIEW
Muhammet Ali Kaplan, Mehmet Ali Nahit Şendur, Ayten Kayı Cangır, Pınar Fırat, Erdem Göker, Saadettin Kılıçkap, Başak Oyan, Ayşim Büge Öz, Feyyaz Özdemir, Gökhan Özyiğit
Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM...
December 2023: Current Problems in Cancer
https://read.qxmd.com/read/37718231/prognostic-role-of-the-peritoneal-cancer-index-in-ovarian-cancer-patients-who-undergo-cytoreductive-surgery-a-meta-analysis
#19
JOURNAL ARTICLE
Shu-Li Yang, Li-Hui Si, Rui-Xin Lin, Shi-Yu Gu, Jia-Hui Li, Jun-Ze Cui, Chu-Han Yan, Abdulkarim Mohamed Farah, Yan Jia
Advanced-stage ovarian cancer is usually associated with peritoneal carcinomatosis. This study evaluates the prognostic role of the Peritoneal Cancer Index (PCI) in predicting the survival of patients with ovarian cancer. A literature search was conducted in electronic databases (Google Scholar, PubMed, Ovid, and Science Direct) and study selection was based on precise eligibility criteria. Random-effects meta-analyses were performed to estimate survival with low and high PCI scores and to pool hazard ratios (HR) of survival between lower and higher PCI scores...
December 2023: Current Problems in Cancer
https://read.qxmd.com/read/36681616/combination-of-immunotherapy-radiotherapy-and-denosumab-as-the-best-approach-even-for-nsclc-poor-prognosis-patients-a-case-report-with-strong-response-prolonged-survival-and-a-review-of-literature
#20
REVIEW
Marco De Felice, Giacinto Turitto, Carola Borrelli, Carmine Menditto, Rodolfo Cangiano
Non-Small Cell Lung Cancer (NSCLC) with bone metastasis and poor performance status has the worst prognosis even in strong PD-L1 expression patients. Treatment approach includes immuno- or chemo-immunotherapy, Radiotherapy (RT) and Bone-Targeted Therapy (BTT) but there is insufficient data to suggest the best time to use each of them, alone or in combination. Using an integrated and synergistic treatment strategy with immunotherapy, radiotherapy, and Denosumab as BTT is probably the best treatment planning for metastatic NSCLC for both good and poor performance status patients, although more data are needed to confirm this approach...
December 2023: Current Problems in Cancer
journal
journal
26997
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.